Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01187186 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01187186 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 16 participants.
The verdict
NCT01187186, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety following oral administration of ASP1941 in subjects with moderate hepatic impairment and in subjects with normal hepatic function based on the Child-Pugh Classification (CPC).
Interventions
- DRUG ASP1941
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01187186
The ClinicalTrials.gov registry entry for NCT01187186 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ASP1941 is the first listed.
NCT01187186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01187186 about?
NCT01187186 is a clinical study titled "A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941". The purpose of this study is to evaluate the pharmacokinetics (PK) and safety following oral administration of ASP1941 in subjects with moderate hepatic impairment and in subjects with normal hepatic function based on the Child-Pugh Classification (CPC).
What is the current status of trial NCT01187186?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-05. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01187186?
The interventions under investigation include: ASP1941 (DRUG).
Who is sponsoring clinical trial NCT01187186?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.